Advertisement

Hormones and Cancer

, Volume 8, Issue 5–6, pp 314–324 | Cite as

Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer

  • Helena Pópulo
  • Bruno Nunes
  • Cristina Sampaio
  • Rui Batista
  • Marta Teixeira Pinto
  • Tiago B. Gaspar
  • Leandro Miranda-Alves
  • Ren-Zhi Cai
  • Xian Yang Zhang
  • Andrew V. Schally
  • Manuel Sobrinho-Simões
  • Paula Soares
Original Paper

Abstract

Growth hormone-releasing hormone (GHRH) is a peptide hormone secreted by the hypothalamus that regulates the synthesis and secretion of growth hormone (GH) in the pituitary. The extra-hypothalamic GHRH and its cognate receptors (GHRHR and splice variants) play a mitogenic role by stimulating cell proliferation and preventing apoptotic cell death. It is well established that GHRH antagonists inhibit the growth, tumorigenicity, and metastasis of various human malignancies. In this work, we studied the effect of two new GHRH antagonists, MIA602 and MIA690, on thyroid cancer. We studied the effect of MIA602 and MIA690 on thyroid cancer in vitro, using human thyroid cancer cell lines, and in vivo, using chicken embryo chorioallantoic membrane (CAM) assays. We found that mRNA for GHRH and GHRH receptor is expressed in thyroid cell lines and in samples of thyroid tumors. Immunohistochemistry confirmed the expression of GHRHR protein in specimens of thyroid tumor. We observed that GHRH antagonists inhibited the growth and increased apoptosis of thyroid cancer cells. In vivo, the antagonists inhibited growth and angiogenesis of engrafted thyroid tumors. Our results suggest that GHRH expression may play a role in growth of thyroid cancer and that GHRH antagonists can be a therapeutic option for thyroid cancer patients.

Keywords

Thyroid cancer Growth hormone-releasing hormone GHRH antagonists Hypothalamic hormone mRNA for GHRH mRNA for GHRH receptors 

Notes

Acknowledgments

This study was supported by the Portuguese Foundation for Science and Technology through a Post-Doc grant to HP (ref.: SFRH/BPD/85249/2012). IPATIMUP integrates the i3S Research Unit, which is partially supported by FCT. This work was financed by Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Further funding was obtained from the project “Advancing cancer research: from basic knowledgment to application”;NORTE-01-0145-FEDER-000029; “Projetos Estruturados de I&D&I,” funded by Norte 2020-Programa Operacional Regional do Norte. A.V.S. was supported by the Medical Research Service of the Department of Veterans Affairs and Department of Medicine, Division of Hematology-Oncology and Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest

Supplementary material

12672_2017_307_MOESM1_ESM.xlsx (19 kb)
Supplementary Table 1 (XLSX 19 kb)

References

  1. 1.
    Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci U S A 99:11866–11871CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, Glassberg MK, Block NL, Lew JI, Elliot SJ, Schally AV (2015) Expression of receptors for pituitary-type growth hormone-releasing hormone (pGHRH-R) in human papillary thyroid cancer cells: effects of GHRH antagonists on matrix Metalloproteinase-2. Horm Cancer 6:100–106CrossRefPubMedGoogle Scholar
  3. 3.
    Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL (2014) Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A 111:1084–1089CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simoes M, Soares P (2012) mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 97:E1139–E1149CrossRefPubMedGoogle Scholar
  5. 5.
    Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A 102:17424–17429CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, Zarandi M, Buchholz S, Huber R, Aigner E, Ritter M, Datz C (2008) Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 33:137–143PubMedGoogle Scholar
  7. 7.
    Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, Kalofoutis A (2003) Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci U S A 100:9512–9517CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G (2012) Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 118:670–680CrossRefPubMedGoogle Scholar
  9. 9.
    Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306CrossRefPubMedGoogle Scholar
  10. 10.
    Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarandi M (2010) A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 31:1839–1846CrossRefPubMedGoogle Scholar
  11. 11.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMedGoogle Scholar
  12. 12.
    Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD (2004) Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41:98–107CrossRefPubMedGoogle Scholar
  13. 13.
    Qin YJ, Chan SO, Chong KK, Li BF, Ng TK, Yip YW, Chen H, Zhang M, Block NL, Cheung HS, Schally AV, Pang CP (2014) Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proc Natl Acad Sci U S A 111:18303–18308CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 97:10561–10566CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L (2011) Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A 108:3755–3760CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S (2012) Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A 109:1655–1660CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467CrossRefPubMedGoogle Scholar
  18. 18.
    Schally AV, Steelman SL, Bowers CY (1965) Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med. Soc Exp Biol Med 119:208–212CrossRefGoogle Scholar
  19. 19.
    Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:33–43CrossRefPubMedGoogle Scholar
  20. 20.
    Siejka A, Barabutis N, Schally AV (2011) GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle 10:3714–3718CrossRefPubMedGoogle Scholar
  21. 21.
    Siejka A, Lawnicka H, Melen-Mucha G, Motylewska E, Komorowski J, Stepien H (2012) Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists. Recent Pat Anti-cancer Drug Discov 7:56–63CrossRefGoogle Scholar
  22. 22.
    Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol 22:395–404CrossRefGoogle Scholar
  23. 23.
    Siriwardana G, Bradford A, Coy D, Zeitler P (2006) Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20:2010–2019CrossRefPubMedGoogle Scholar
  24. 24.
    Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG (2014) Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle 13:2790–2797CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zarandi M, Cai R, Kovacs M, Popovics P, Szalontay L, Cui T, Sha W, Jaszberenyi M, Varga J, Zhang X, Block NL, Rick FG, Halmos G, Schally AV (2017) Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides 89:60–70CrossRefPubMedGoogle Scholar
  26. 26.
    Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV (1994) Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 91:12298–12302CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Helena Pópulo
    • 1
    • 2
  • Bruno Nunes
    • 1
    • 2
    • 3
  • Cristina Sampaio
    • 1
    • 2
  • Rui Batista
    • 1
    • 2
    • 4
  • Marta Teixeira Pinto
    • 1
    • 2
  • Tiago B. Gaspar
    • 1
    • 2
  • Leandro Miranda-Alves
    • 1
    • 2
    • 3
  • Ren-Zhi Cai
    • 5
    • 6
  • Xian Yang Zhang
    • 5
    • 6
  • Andrew V. Schally
    • 5
    • 6
    • 7
  • Manuel Sobrinho-Simões
    • 1
    • 2
    • 8
    • 9
  • Paula Soares
    • 1
    • 2
    • 8
  1. 1.Institute of Molecular Pathology and ImmunologyUniversity of Porto (IPATIMUP)PortoPortugal
  2. 2.Institute for Research and Innovation in Health (I3S)University of PortoPortoPortugal
  3. 3.Experimental Endocrinology-GPEEx Group, Institute of Biomedical Sciences and Postgraduate Endocrinology, Medical FacultyFederal University of Rio de JaneiroRio de JaneiroBrazil
  4. 4.Medical FacultyUniversity of PortoPortoPortugal
  5. 5.Veterans Affairs Medical Center MiamiMiamiUSA
  6. 6.Department of Medicine, Divisions of Endocrinology and Hematology-Oncology, Sylvester Comprehensive Cancer Center and Interdisciplinary Stem Cell InstituteUniversity of Miami, School of MedicineMiamiUSA
  7. 7.Department of Pathology, Divisions of Endocrinology and Hematology-Oncology, Sylvester Comprehensive Cancer Center and Interdisciplinary Stem Cell InstituteUniversity of Miami, School of MedicineMiamiUSA
  8. 8.Department of Pathology and Oncology, Medical FacultyUniversity of PortoPortoPortugal
  9. 9.Department of Pathology, Hospital S. JoãoPortoPortugal

Personalised recommendations